

Fuyuhiko Tamanoi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4416643/publications.pdf>

Version: 2024-02-01

122
papers

11,611
citations

41627

51
h-index

31191

106
g-index

124
all docs

124
docs citations

124
times ranked

16360
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Accumulation of PIP-Based KRAS Inhibitor KR12 Evaluated by the Use of a Simple, Versatile Chicken Egg Tumor Model. <i>Cancers</i> , 2022, 14, 951.	1.7	1
2	Fiber-Optic Based Laser Wakefield Accelerated Electron Beams and Potential Applications in Radiotherapy Cancer Treatments. <i>Photonics</i> , 2022, 9, 403.	0.9	4
3	Reducing particle size of biodegradable nanomaterial for efficient curcumin loading. <i>Journal of Materials Science</i> , 2021, 56, 3713-3722.	1.7	9
4	Magnetic Nanoparticles and Alternating Magnetic Field for Cancer Therapy. <i>Fundamental Biomedical Technologies</i> , 2021, , 165-179.	0.2	1
5	Facile synthesis of biodegradable mesoporous functionalized-organosilica nanoparticles for enhancing the anti-cancer efficiency of cordycepin. <i>Microporous and Mesoporous Materials</i> , 2021, 315, 110913.	2.2	4
6	Construction of Boronophenylalanine-Loaded Biodegradable Periodic Mesoporous Organosilica Nanoparticles for BNCT Cancer Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2251.	1.8	15
7	Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 9656-9666.	4.0	39
8	Iodine containing porous organosilica nanoparticles trigger tumor spheroids destruction upon monochromatic X-ray irradiation: DNA breaks and K-edge energy X-ray. <i>Scientific Reports</i> , 2021, 11, 14192.	1.6	10
9	The CAM Model for CIC-DUX4 Sarcoma and Its Potential Use for Precision Medicine. <i>Cells</i> , 2021, 10, 2613.	1.8	8
10	Recent Development to Explore the Use of Biodegradable Periodic Mesoporous Organosilica (BPMO) Nanomaterials for Cancer Therapy. <i>Pharmaceutics</i> , 2020, 12, 890.	2.0	19
11	Studies on the Exposure of Gadolinium Containing Nanoparticles with Monochromatic X-rays Drive Advances in Radiation Therapy. <i>Nanomaterials</i> , 2020, 10, 1341.	1.9	10
12	Biodegradable Periodic Mesoporous Organosilica (BPMO) Loaded with Daunorubicin: A Promising Nanoparticle-Based Anticancer Drug. <i>ChemMedChem</i> , 2020, 15, 593-599.	1.6	33
13	Cytosolic and mitochondrial ROS production resulted in apoptosis induction in breast cancer cells treated with Crocin: The role of FOXO3a, PTEN and AKT signaling. <i>Biochemical Pharmacology</i> , 2020, 177, 113999.	2.0	37
14	Destruction of tumor mass by gadolinium-loaded nanoparticles irradiated with monochromatic X-rays: Implications for the Auger therapy. <i>Scientific Reports</i> , 2019, 9, 13275.	1.6	29
15	Patient Derived Chicken Egg Tumor Model (PDcE Model): Current Status and Critical Issues. <i>Cells</i> , 2019, 8, 440.	1.8	38
16	Relationship between the glutathione-responsive degradability of thiol-organosilica nanoparticles and the chemical structures. <i>Journal of Materials Research</i> , 2019, 34, 1266-1278.	1.2	15
17	Recent excitements in the study of the CAM assay. <i>The Enzymes</i> , 2019, 46, 1-9.	0.7	7
18	Biodegradability of Disulfide-Organosilica Nanoparticles Evaluated by Soft X-ray Photoelectron Spectroscopy: Cancer Therapy Implications. <i>ACS Applied Nano Materials</i> , 2019, 2, 479-488.	2.4	39

#	ARTICLE	IF	CITATIONS
19	Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 1381-1394.	1.7	75
20	Isolation and characterization of the primary epithelial breast cancer cells and the adjacent normal epithelial cells from Iranian women's breast cancer tumors. <i>Cytotechnology</i> , 2018, 70, 625-639.	0.7	12
21	Miniaturization of thiol-organosilica nanoparticles induced by an anionic surfactant. <i>Journal of Colloid and Interface Science</i> , 2018, 526, 51-62.	5.0	16
22	Tumor Targeting and Tumor Growth Inhibition Capability of Mesoporous Silica Nanoparticles in Mouse Models. <i>The Enzymes</i> , 2018, 44, 61-82.	0.7	3
23	Anticancer Drug Delivery Capability of Biodegradable PMO in the Chicken Egg Tumor Model. <i>The Enzymes</i> , 2018, 44, 103-116.	0.7	3
24	Overview of Studies Regarding Mesoporous Silica Nanomaterials and Their Biomedical Application. <i>The Enzymes</i> , 2018, 43, 1-10.	0.7	24
25	An oncogenic mutant of RHEB, RHEB Y35N, exhibits an altered interaction with BRAF resulting in cancer transformation. <i>BMC Cancer</i> , 2018, 18, 69.	1.1	8
26	Chick chorioallantoic membrane assay as an in vivo model to study the effect of nanoparticle-based anticancer drugs in ovarian cancer. <i>Scientific Reports</i> , 2018, 8, 8524.	1.6	101
27	GTP-Binding Protein Rheb. , 2018, , 2288-2293.		0
28	Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2017, 13, 965-976.	1.7	67
29	A novel inhibitor of farnesyltransferase with a zinc site recognition moiety and a farnesyl group. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 3862-3866.	1.0	28
30	Exploiting Enzyme Alterations in Cancer for Drug Activation, Drug Delivery, and Nanotherapy. <i>The Enzymes</i> , 2017, 42, 153-172.	0.7	5
31	In vitro delivery of calcium ions by nanogated mesoporous silica nanoparticles to induce cancer cellular apoptosis. <i>Molecular Systems Design and Engineering</i> , 2017, 2, 384-392.	1.7	12
32	Mevalonate Pathway and Human Cancers. <i>Current Molecular Pharmacology</i> , 2017, 10, 77-85.	0.7	103
33	In vivo Tumor Suppression Efficacy of Mesoporous Silica Nanoparticle-Based Drug Delivery System: Enhanced Efficacy by Folate Modification. , 2017, , 215-234.		0
34	Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. <i>Chemistry - A European Journal</i> , 2016, 22, 14806-14811.	1.7	81
35	Periodic Mesoporous Organosilica Nanoparticles with Controlled Morphologies and High Drug/Dye Loadings for Multicargo Delivery in Cancer Cells. <i>Chemistry - A European Journal</i> , 2016, 22, 9607-9615.	1.7	46
36	Frontispiece: Biodegradable Oxamide-Phenylene-Based Mesoporous Organosilica Nanoparticles with Unprecedented Drug Payloads for Delivery in Cells. <i>Chemistry - A European Journal</i> , 2016, 22, .	1.7	0

#	ARTICLE	IF	CITATIONS
37	Protein-gold clusters-capped mesoporous silica nanoparticles for high drug loading, autonomous gemcitabine/doxorubicin co-delivery, and in-vivo tumor imaging. <i>Journal of Controlled Release</i> , 2016, 229, 183-191.	4.8	149
38	GTP-Binding Protein Rheb. , 2016, , 1-6.		0
39	Significance of filamin A in mTORC2 function in glioblastoma. <i>Molecular Cancer</i> , 2015, 14, 127.	7.9	52
40	Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. <i>PLoS ONE</i> , 2015, 10, e0137595.	1.1	9
41	Rheb Protein Binds CAD (Carbamoyl-phosphate Synthetase 2, Aspartate Transcarbamoylase, and) Tj ETQq1 1 0.784314 rgBT /Overloc Localization and Carbamoyl-phosphate Synthetase (CPSase) Activity. <i>Journal of Biological Chemistry</i> , 2015. 290. 1096-1105.	1.6	24
42	Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. <i>BMC Cancer</i> , 2015, 15, 381.	1.1	26
43	Development of mesoporous silica-based nanoparticles with controlled release capability for cancer therapy. <i>Advanced Drug Delivery Reviews</i> , 2015, 95, 40-49.	6.6	228
44	Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2015, 11, 1657-1666.	1.7	51
45	How Phytochemicals Prevent Chemical Carcinogens and/or Suppress Tumor Growth?. <i>The Enzymes</i> , 2015, 37, 1-42.	0.7	12
46	Functional Nanovalves on Protein-Coated Nanoparticles for In vitro and In vivo Controlled Drug Delivery. <i>Small</i> , 2015, 11, 319-328.	5.2	65
47	Introduction. <i>The Enzymes</i> , 2014, 36, 1-6.	0.7	0
48	Fission yeast arrestin-related trafficking adaptor, Arn1/Any1, is ubiquitinated by Pub1 E3 ligase and regulates endocytosis of Cat1 amino acid transporter. <i>Biology Open</i> , 2014, 3, 542-552.	0.6	24
49	Hybrid Mesoporous Silica Nanoparticles with pH-Operated and Complementary H-Bonding Caps as an Autonomous Drug-Delivery System. <i>Chemistry - A European Journal</i> , 2014, 20, 9372-9380.	1.7	40
50	Anticancer Effect and Molecular Targets of Saffron Carotenoids. <i>The Enzymes</i> , 2014, 36, 57-86.	0.7	17
51	Drug Release from Three-Dimensional Cubic Mesoporous Silica Nanoparticles Controlled by Nanoimpellers. <i>Zeitschrift Fur Anorganische Und Allgemeine Chemie</i> , 2014, 640, 588-594.	0.6	13
52	Two-Photon-Triggered Drug Delivery via Fluorescent Nanovalves. <i>Small</i> , 2014, 10, 1752-1755.	5.2	106
53	Recent progress in the study of the Rheb family GTPases. <i>Cellular Signalling</i> , 2014, 26, 1950-1957.	1.7	64
54	In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. <i>BMC Cancer</i> , 2013, 13, 198.	1.1	28

#	ARTICLE	IF	CITATIONS
55	Two-Photon-Triggered Drug Delivery in Cancer Cells Using Nanoimpellers. <i>Angewandte Chemie - International Edition</i> , 2013, 52, 13813-13817.	7.2	94
56	The Ras Superfamily G-Proteins. <i>The Enzymes</i> , 2013, 33 Pt A, 1-14.	0.7	13
57	Involvement of Lysosomal Exocytosis in the Excretion of Mesoporous Silica Nanoparticles and Enhancement of the Drug Delivery Effect by Exocytosis Inhibition. <i>Small</i> , 2013, 9, 697-704.	5.2	137
58	A Two-Hybrid Approach to Identify Inhibitors of the RAS-RAF Interaction. <i>The Enzymes</i> , 2013, 33 Pt A, 213-248.	0.7	7
59	Recent Progress in Developing Small Molecule Inhibitors Designed to Interfere with Ras Membrane Association. <i>The Enzymes</i> , 2013, 34 Pt. B, 181-200.	0.7	12
60	Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase. <i>Journal of Cell Science</i> , 2012, 125, 5840-5849.	1.2	64
61	Nanoparticle-Based Delivery of siRNA and miRNA for Cancer Therapy. <i>The Enzymes</i> , 2012, , 185-203.	0.7	3
62	Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. <i>Therapeutic Delivery</i> , 2012, 3, 389-404.	1.2	62
63	Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. <i>Nanoscale</i> , 2012, 4, 3482.	2.8	24
64	Tailoring the biodegradability of porous silicon nanoparticles. <i>Journal of Biomedical Materials Research - Part A</i> , 2012, 100A, 3416-3421.	2.1	46
65	In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2012, 8, 212-220.	1.7	192
66	PAK1 Kinase Promotes Cell Motility and Invasiveness through CRK-II Serine Phosphorylation in Non-Small Cell Lung Cancer Cells. <i>PLoS ONE</i> , 2012, 7, e42012.	1.1	41
67	Global Analysis of Prenylated Proteins by the Use of a Tagging via Substrate Approach. <i>The Enzymes</i> , 2011, , 195-206.	0.7	0
68	Identification and Characterization of Mechanism of Action of P61-E7, a Novel Phosphine Catalysis-Based Inhibitor of Geranylgeranyltransferase-I. <i>PLoS ONE</i> , 2011, 6, e26135.	1.1	17
69	Activating mutations of TOR (target of rapamycin). <i>Genes To Cells</i> , 2011, 16, 141-151.	0.5	60
70	Synthesis of Biomolecule-Modified Mesoporous Silica Nanoparticles for Targeted Hydrophobic Drug Delivery to Cancer Cells. <i>Small</i> , 2011, 7, 1816-1826.	5.2	204
71	Ras Signaling in Yeast. <i>Genes and Cancer</i> , 2011, 2, 210-215.	0.6	55
72	Biocompatibility, Biodistribution, and Drug-Delivery Efficiency of Mesoporous Silica Nanoparticles for Cancer Therapy in Animals. <i>Small</i> , 2010, 6, 1794-1805.	5.2	947

#	ARTICLE	IF	CITATIONS
73	Mesoporous Silica Nanoparticles Facilitate Delivery of siRNA to Shutdown Signaling Pathways in Mammalian Cells. <i>Small</i> , 2010, 6, 1185-1190.	5.2	215
74	Fission yeast TORC1 regulates phosphorylation of ribosomal S6 proteins in response to nutrients and its activity is inhibited by rapamycin. <i>Journal of Cell Science</i> , 2010, 123, 777-786.	1.2	82
75	Rheb G-Proteins and the Activation of mTORC1. <i>The Enzymes</i> , 2010, 27, 39-56.	0.7	29
76	Conservation of the Tsc/Rheb/TORC1/S6K/S6 Signaling in Fission Yeast. <i>The Enzymes</i> , 2010, 28, 167-187.	0.7	10
77	Autonomous in Vitro Anticancer Drug Release from Mesoporous Silica Nanoparticles by pH-Sensitive Nanovalves. <i>Journal of the American Chemical Society</i> , 2010, 132, 12690-12697.	6.6	550
78	Specific Activation of mTORC1 by Rheb G-protein in Vitro Involves Enhanced Recruitment of Its Substrate Protein. <i>Journal of Biological Chemistry</i> , 2009, 284, 12783-12791.	1.6	179
79	<i>In vivo</i> antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1218-1226.	1.9	72
80	Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome. <i>Journal of Lipid Research</i> , 2009, 50, 126-134.	2.0	33
81	A novel approach to tag and identify geranylgeranylated proteins. <i>Electrophoresis</i> , 2009, 30, 3598-3606.	1.3	63
82	Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. <i>Journal of the American Ceramic Society</i> , 2009, 92, s2-s10.	1.9	101
83	Silica nanoparticles as a delivery system for nucleic acid-based reagents. <i>Journal of Materials Chemistry</i> , 2009, 19, 6308.	6.7	72
84	The Tsc/Rheb signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast. <i>Molecular Genetics and Genomics</i> , 2008, 279, 441-450.	1.0	41
85	Light-Activated Nanopump-Controlled Drug Release in Cancer Cells. <i>Small</i> , 2008, 4, 421-426.	5.2	430
86	Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery. <i>ACS Nano</i> , 2008, 2, 889-896.	7.3	1,758
87	Characterization of the Rheb-mTOR Signaling Pathway in Mammalian Cells: Constitutive Active Mutants of Rheb and mTOR. <i>Methods in Enzymology</i> , 2008, 438, 307-320.	0.4	38
88	Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Alkenoate-derived Compounds. <i>Journal of Biological Chemistry</i> , 2008, 283, 9571-9579.	1.6	79
89	The TSC/Rheb/TOR Signaling Pathway in Fission Yeast and Mammalian Cells: Temperature Sensitive and Constitutive Active Mutants of TOR. <i>Cell Cycle</i> , 2007, 6, 1692-1695.	1.3	41
90	Loss of the TOR Kinase Tor2 Mimics Nitrogen Starvation and Activates the Sexual Development Pathway in Fission Yeast. <i>Molecular and Cellular Biology</i> , 2007, 27, 3154-3164.	1.1	181

#	ARTICLE	IF	CITATIONS
91	Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3514-3519.	3.3	133
92	Small-Molecule Inhibitors of Protein Geranylgeranyltransferase Type I. <i>Journal of the American Chemical Society</i> , 2007, 129, 5843-5845.	6.6	196
93	Mesoporous Silica Nanoparticles as a Delivery System for Hydrophobic Anticancer Drugs. <i>Small</i> , 2007, 3, 1341-1346.	5.2	927
94	Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. <i>Nanobiotechnology</i> , 2007, 3, 89-95.	1.2	175
95	Chemical Biology/ Chemical Genetics/ Chemical Genomics: Importance of Chemical Library. <i>Chem-Bio Informatics Journal</i> , 2007, 7, 49-68.	0.1	6
96	Therapeutic intervention based on protein prenylation and associated modifications. <i>Nature Chemical Biology</i> , 2006, 2, 518-528.	3.9	176
97	Using <i>Drosophila</i> and Yeast Genetics to Investigate a Role for the Rheb GTPase in Cell Growth. <i>Methods in Enzymology</i> , 2006, 407, 443-454.	0.4	3
98	Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress. <i>Journal of Cell Science</i> , 2006, 119, 4285-4292.	1.2	59
99	Ras Family G-Proteins in <i>Saccharomyces Cerevisiae</i> and <i>Schizosaccharomyces Pombe.</i> , 2006, , 227-256.		1
100	Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. <i>Molecular Microbiology</i> , 2005, 58, 1074-1086.	1.2	83
101	Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 918-926.	1.9	55
102	A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 12479-12484.	3.3	322
103	The Rheb family of GTP-binding proteins. <i>Cellular Signalling</i> , 2004, 16, 1105-1112.	1.7	175
104	Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. <i>Glia</i> , 2004, 47, 180-188.	2.5	69
105	A novel metal-Chelating inhibitor of protein farnesyltransferase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 1523-1526.	1.0	20
106	<i>Drosophila</i> Rheb GTPase is required for cell cycle progression and cell growth. <i>Journal of Cell Science</i> , 2003, 116, 3601-3610.	1.2	147
107	Identification of Dominant Negative Mutants of Rheb GTPase and Their Use to Implicate the Involvement of Human Rheb in the Activation of p70S6K. <i>Journal of Biological Chemistry</i> , 2003, 278, 39921-39930.	1.6	105
108	Characterization of Rheb functions using yeast and mammalian systems. <i>Methods in Enzymology</i> , 2001, 333, 217-231.	0.4	21

#	ARTICLE	IF	CITATIONS
109	Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. <i>Molecular Microbiology</i> , 2001, 41, 1339-1347.	1.2	62
110	Farnesylated proteins and cell cycle progression. <i>Journal of Cellular Biochemistry</i> , 2001, 84, 64-70.	1.2	56
111	Effects of farnesyltransferase inhibitors on cell cycle progression of human cancer cells. <i>Gene Function & Disease</i> , 2001, 2, 99-107.	0.3	0
112	Spatial regulation of the exocyst complex by Rho1 GTPase. <i>Nature Cell Biology</i> , 2001, 3, 353-360.	4.6	288
113	Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. <i>Oncogene</i> , 2000, 19, 3059-3068.	2.6	96
114	The Saccharomyces cerevisiae Rheb G-protein Is Involved in Regulating Canavanine Resistance and Arginine Uptake. <i>Journal of Biological Chemistry</i> , 2000, 275, 11198-11206.	1.6	119
115	Protein Farnesylation Is Critical for Maintaining Normal Cell Morphology and Canavanine Resistance in Schizosaccharomyces pombe. <i>Journal of Biological Chemistry</i> , 2000, 275, 429-438.	1.6	35
116	Neurofibromatosis 2 tumour suppressor schwannomin interacts with β II-spectrin. <i>Nature Genetics</i> , 1998, 18, 354-359.	9.4	145
117	Characterization of the geranylgeranyl transferase type I from Schizosaccharomyces pombe. <i>Molecular Microbiology</i> , 1998, 29, 1357-1367.	1.2	26
118	Advances in the development of farnesyltransferase inhibitors: Substrate recognition by protein farnesyltransferase. <i>Journal of Cellular Biochemistry</i> , 1997, 67, 12-19.	1.2	10
119	Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. <i>Human Genetics</i> , 1996, 99, 88-92.	1.8	105
120	Prenylation of RAS and Inhibitors of Prenyltransferases. , 1996, , 95-137.		21
121	Inhibitors of ras farnesyltransferases. <i>Trends in Biochemical Sciences</i> , 1993, 18, 349-353.	3.7	167
122	Genetic Analysis of FTase and GGTase I and Natural Product Farnesyltransferase Inhibitors. , 0, , 145-157.		1